Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanezumab - Eli Lilly and Company/Pfizer

Drug Profile

Tanezumab - Eli Lilly and Company/Pfizer

Alternative Names: PF-04383119; PF-4383119; RI-624; RN-624

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rinat Neuroscience
  • Developer Pfizer
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Cancer pain; Musculoskeletal pain
  • Suspended Diabetic neuropathies
  • No development reported Postherpetic neuralgia

Most Recent Events

  • 14 Nov 2019 Pfizer plans a phase II trial for Cancer pain in USA (SC) (NCT04163419)
  • 30 Jul 2019 Eli Lilly plans to make regulatory submissions in the EU and Japan for Musculoskeletal pain
  • 29 Jul 2019 Eli Lilly plans to make regulatory submissions to the US FDA for Musculoskeletal pain in fourth quarter of 2019 or early 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top